HAMBURG, Germany and OXFORD, England, October 9 /PRNewswire-FirstCall/ -- Evotec AG is going to hold an R&D Update in London on Tuesday 16 October 2007 at 13.00 pm BST (14.00 pm CET, 08.00 am US time East Coast) which will be broadcast live on the internet.
Jorn Aldag, (President & Chief Executive Officer), Dr John Kemp, (Chief Research & Development Officer) and Dr Tim Tasker, (EVP Clinical Development) will provide an update on the status and development plans for Evotec’s Clinical Programs and Discovery Projects. In addition, we are delighted to announce that Dr Michael G Kelly, (SVP Research & Development) at Renovis, will present the Renovis Pipeline Programs.
To join the audio webcast and to access the presentation slides you will find a link on our home page http://www.evotec.com shortly before the event.
The on-demand version of the webcast will be available on our website: http://www.evotec.com - Investors - Webcasts.
About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through research collaborations, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.
In proprietary projects, Evotec specialises in finding new treatments for diseases of the Central Nervous System. Evotec has three programmes in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer’s disease and/or pain, and EVT 302, a MAO-B inhibitor in development for smoking cessation.
On 19 September 2007, Evotec announced that it has entered into a definitive agreement under which Evotec will acquire Renovis, a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of pain and inflammatory diseases.
anne.hennecke@evotec.com
CONTACT: Contact: Evotec AG, Anne Hennecke, SVP, Investor Relations &
Corporate Communications, Phone: +49(0)40-56081-286, Fax:
+49(0)40-56081-333, E-Mail: anne.hennecke@evotec.com
